ERBB2 and breast cancer: For instance, in a cohort of 6,500 breast cancer patients, higher DEPTH2 scores were predominantly observed in triple-negative and HER2-positive subtypes and were significantly associated with proliferative signaling and diverse immune cell infiltrates (28).